Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

ClinicalTrials.gov ID: NCT02452190

Public ClinicalTrials.gov record NCT02452190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.

Study identification

NCT ID
NCT02452190
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
468 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 27, 2015
Primary completion
Dec 3, 2017
Completion
Jan 30, 2018
Last update posted
Nov 8, 2021

2015 – 2018

United States locations

U.S. sites
69
U.S. states
29
U.S. cities
65
Facility City State ZIP Site status
Teva Investigational Site 13212 Birmingham Alabama 35209
Teva Investigational Site 13241 Flagstaff Arizona 86001
Teva Investigational Site 13194 Glendale Arkansas 85306
Teva Investigational Site 13215 Bakersfield California 93301
Teva Investigational Site 13181 Canoga Park California 91303
Teva Investigational Site 13254 Fresno California 93720
Teva Investigational Site 13216 Huntington Beach California 92647
Teva Investigational Site 13247 Long Beach California 90813
Teva Investigational Site 13205 Napa California 94558
Teva Investigational Site 13764 San Jose California 95117
Teva Investigational Site 13252 Stockton California 95207
Teva Investigational Site 13251 Walnut Creek California 94598
Teva Investigational Site 13229 Denver Colorado 80206
Teva Investigational Site 13766 Waterbury Connecticut 06708
Teva Investigational Site 13196 Aventura Florida 33180
Teva Investigational Site 13256 Fort Lauderdale Florida 33308
Teva Investigational Site 13203 Kissimmee Florida 34741
Teva Investigational Site 13197 Miami Florida 33125
Teva Investigational Site 13220 Miami Florida 33155
Teva Investigational Site 13243 Miami Florida 33176
Teva Investigational Site 13233 New Port Richey Florida 34653
Teva Investigational Site 13201 Orlando Florida 32811
Teva Investigational Site 13250 Orlando Florida 32819
Teva Investigational Site 13246 Pembroke Pines Florida 33029
Teva Investigational Site 13208 Tallahassee Florida 32308
Teva Investigational Site 13255 Tampa Florida 33607
Teva Investigational Site 13765 Albany Georgia 31707
Teva Investigational Site 13249 Buford Georgia 30518
Teva Investigational Site 13763 Lawrenceville Georgia 30045
Teva Investigational Site 13230 Chicago Illinois 60612
Teva Investigational Site 13211 Normal Illinois 61761
Teva Investigational Site 13235 Shiloh Illinois 62269
Teva Investigational Site 13202 Michigan City Indiana 46360
Teva Investigational Site 13225 Lenexa Kansas 66215
Teva Investigational Site 13222 Owensboro Kentucky 42301
Teva Investigational Site 13191 Lafayette Louisiana 70503
Teva Investigational Site 13200 North Dartmouth Massachusetts 02747
Teva Investigational Site 13226 Biloxi Mississippi 39531
Teva Investigational Site 13204 St Louis Missouri 63143
Teva Investigational Site 13258 Boys Town Nebraska 68010
Teva Investigational Site 13769 Belleville New Jersey 07109
Teva Investigational Site 13210 Ocean City New Jersey 07712
Teva Investigational Site 13188 New Hyde Park New York 11040
Teva Investigational Site 13232 New York New York 10016
Teva Investigational Site 13767 New York New York 11570
Teva Investigational Site 13186 Cincinnati Ohio 45267
Teva Investigational Site 13253 Cleveland Ohio 44106
Teva Investigational Site 13240 Toledo Ohio 43606
Teva Investigational Site 13259 Edmond Oklahoma 73034
Teva Investigational Site 13238 Oklahoma City Oklahoma 73112
Teva Investigational Site 13195 Medford Oregon 97504
Teva Investigational Site 13242 Bethlehem Pennsylvania 18020
Teva Investigational Site 13218 Jenkintown Pennsylvania 19046
Teva Investigational Site 13189 Philadelphia Pennsylvania 19107
Teva Investigational Site 13190 Pittsburgh Pennsylvania 15241
Teva Investigational Site 13209 East Providence Rhode Island ?02914
Teva Investigational Site 13217 Lincoln Rhode Island 02865
Teva Investigational Site 13223 Knoxville Tennessee 37919
Teva Investigational Site 13185 Arlington Texas 76018
Teva Investigational Site 13199 Corsicana Texas 75110
Teva Investigational Site 13260 Dallas Texas 75225
Teva Investigational Site 13224 San Antonio Texas 78229
Teva Investigational Site 13184 Waco Texas 76712
Teva Investigational Site 13187 Provo Utah 84604
Teva Investigational Site 13207 Abingdon Virginia 24210
Teva Investigational Site 13183 Fairfax Virginia 22030
Teva Investigational Site 13257 Falls Church Virginia 22044
Teva Investigational Site 13239 Richmond Virginia 23233
Teva Investigational Site 13227 Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02452190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02452190 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →